Pacira BioSciences to Present at Two Healthcare Conferences in November
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced participation in upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced participation in upcoming healthcare conferences. The company will engage in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 15 at 8:00 AM GMT and the 34th Annual Piper Sandler Healthcare Conference on November 29 at 2:30 PM ET. Live audio can be accessed on their website, with replays available for two weeks post-event. Pacira is dedicated to offering non-opioid pain management options and has three commercial products for pain relief.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was +0.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
- Jefferies London Healthcare Conference on Tuesday, November 15th at 8:00AM GMT (3:00AM ET).
- 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29th at 2:30PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.